TTSH, Thermo Fisher collaboration advances precision medicine, genetic testing
Singapore’s Tan Tock Seng Hospital (TTSH) is partnering with Thermo Fisher Scientific to enhance clinical research through advanced multiple-gene testing, a field known as pharmacogenomics (PGx). PGx testing focuses on how genes influence responses to medications, aiding clinicians in making informed treatment decisions for patients. TTSH, a pioneer in PGx testing, previously offered single-gene and small-panel tests, which led to multiple tests and higher costs. The collaboration with Thermo Fisher allows for simultaneous assessment of multiple genes and the use of polygenic risk scores (PRS) to measure disease risk based on genetics, reducing the need for multiple tests and costs.
The partnership expands TTSH’s Molecular Diagnostic Laboratory (MDL) capabilities, potentially leading to innovative population health solutions. In 2024, MDL and TTSH will conduct a unique three-year research trial using PRS to predict heart disease in the local population. The precision medicine approach aligns with Singapore’s Research, Innovation, and Enterprise 2025 vision, aiming for preventative healthcare in line with the Healthier SG reform plan. Dr. Goh Liuh Ling of TTSH emphasizes early intervention and cost savings, while Fadjar Linawati of Thermo Fisher highlights the shift to personalized medicine. Educational programs and training will further raise awareness and develop local talent in navigating transformative healthcare approaches.
Category: Uncategorized
Subscribe
If you enjoyed this article, subscribe to receive more just like it.
